13th Annual Fall Midwest Thoracic and GI Oncology Conference


 

Targeting ALK in NSCLC: Alectinib 1st Line Treatment Choice, New Promising Inhibitor, and ALK Inhibitor + IO Toxic Combo

362 views
December 19, 2018
Comments 0
Login to view comments. Click here to Login